Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clebopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 1.00 |
| ▸ | HTR4 known ✓ | Q13639 | 6/20 | 0.76 |
| ▸ | DRD4 | P21917 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clebopride SCHEMBL25259199 | 1.00 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL9867307 | 0.99 | DRD4 (0.98) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL11533888 | 0.96 | DRD4 (0.92) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL4537448 | 0.95 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL2323732 | 0.95 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL2323725 | 0.95 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL11472928 | 0.94 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL3701285 | 0.91 | DRD4 (0.83) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL14454215 | 0.89 | DRD4 (0.80) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL11463635 | 0.89 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4187 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024005132-A1 | PHARMACEUTICAL COMPOSITION | マルホ株式会社 | 2024-01-04 | — | — | WO | claimed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4035668-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| EP-1121099-A1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI-SYNTHELABO (FR) | 2001-08-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000023045-A1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI-SYNTHELABO (FR) | 2000-04-27 | — | — | WO | claimed |
| EP-0707492-A1 | H 2? ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO. INC. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001803-A1 | H2 ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | claimed |
| US-4978531-A | ANTIEMETICS | FORDONAL, S.A. (ES) | 1990-12-18 | — | — | US | claimed |
| EP-0303445-A1 | Clebopride transdermal patch | WALTON S.A. (ES) | 1989-02-15 | — | — | EP | claimed |